Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Stellantis and Koç Holding Strengthen Tofaş and Enhance 2-03-2023, 00:09

Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023 4-08-2023, 04:00